Head-To-Head Comparison Of Subcutaneous Abatacept Versus Adalimumab On Background Methotrexate In RA: Blinded Two Year Results From The Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjectswith Background Methotrexate) study

被引：0
|
作者：
Weinblatt, Michael E. [1 ]
Schiff, Michael H. [2 ]
Valente, Robert [3 ]
van der Heijde, Desiree M. [4 ]
Citera, Gustavo [5 ]
Elegbe, Ayanbola [6 ]
Maldonado, Michael A. [6 ]
Fleischmann, Roy M. [7 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Univ Colorado, Denver, CO 80202 USA
[3] Arthrit Ctr Nebraska, Lincoln, NE USA
[4] Leiden Univ, Med Ctr, Leiden, Netherlands
[5] Inst Rehabil Psicofis, Buenos Aires, DF, Argentina
[6] Bristol Myers Squibb Co, Princeton, NJ USA
[7] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2326
引用
收藏
页码：S991 / S992
页数：2
相关论文
共 47 条
  • [21] Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
    Fleischmann, Roy
    Weinblatt, Michael E.
    Schiff, Michael
    Khanna, Dinesh
    Maldonado, Michael A.
    Nadkarni, Anagha
    Furst, Daniel E.
    [J]. ARTHRITIS CARE & RESEARCH, 2016, 68 (07) : 907 - 913
  • [22] COST EFFECTIVENESS ANALYSIS OF ABATACEPT COMPARED WITH ADALIMUMAB ON BACKGROUND METHOTREXATE IN BIOLOGIC-NAIVE RA ADULT PATIENTS BY ANTI-CYCLIC CITRULLINATED PEPTIDE-POSITIVE SUBGROUPS
    Alemao, E.
    Schiff, M.
    Johal, S.
    Al, M.
    Rutten-Van Molken, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 319 - 319
  • [23] Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis
    Alemao, Evo
    Johal, Sukhvinder
    Al, Maiwenn J.
    Rutten-van Molken, Maureen
    [J]. VALUE IN HEALTH, 2018, 21 (02) : 193 - 202
  • [24] Reanalysis of the multi-biomarker disease activity score for assessing disease activity in the Abatacept versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate study: comment on the article by Fleischmann et al
    Curtis, Jeffrey R.
    Wright, Grace C.
    Strand, Vibeke
    Davis, Charles S.
    Hitraya, Elena
    Sasso, Eric H.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69 (04) : 863 - 865
  • [25] THE EFFECT OF HLA-DRB1 RISK ALLELES ON THE CLINICAL EFFICACY AND SAFETY OF ABATACEPT IN SEROPOSITIVE, BIOLOGIC-NAIVE PATIENTS WITH EARLY, MODERATE-TO-SEVERE RA TREATED WITH ABATACEPT OR ADALIMUMAB: DATA FROM THE OPEN-LABEL SWITCH PERIOD OF THE HEAD-TO-HEAD SINGLE-BLINDED 'EARLY AMPLE' TRIAL
    Rigby, W.
    Buckner, J.
    Bridges, S. L., Jr.
    Nys, M.
    Gao, S.
    Polinsky, M.
    Ray, N.
    Bykerk, V.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 291 - 291
  • [26] Development of Abatacept- and Adalimumab-Specific Predictive Models of Response to Therapy in RA Using Data from a Head-to-Head Study
    Bandyopadhyay, S.
    Maldonado, M. A.
    Ammar, R.
    Schiff, Michael
    Weinblatt, Michael
    Fleischmann, Roy
    Connolly, S. E.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [27] THE EFFECT OF HLA-DRB1 RISK ALLELES ON THE CLINICALEFFICACY OF ABATACEPT AND ADALIMUMAB IN SEROPOSITIVE BIOLOGIC-NAIVE PATIENTSWITH EARLY, MODERATE-TO-SEVERE RA: DATA FROM A HEAD-TO-HEAD SINGLE-BLINDEDTRIAL
    Rigby, William
    Buckner, Jane
    Bridges, Lou
    Nys, Marleen
    Gao, Sheng
    Polinsky, Martin
    Johnsen, Alyssa
    Ray, Neelanjana
    Bykerk, Vivian
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 263 - 264
  • [28] The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naive Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial
    Buckner, Jane
    Bykerk, Vivian
    Holers, V. Michael
    Bridges, S. Louis
    Rigby, William
    Gao, Sheng
    Nys, Marleen
    Ray, Neelanjana
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [29] Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study
    Taylor, Peter C.
    Keystone, Edward C.
    van der Heijde, D.
    Tanaka, Yoshiya
    Ishii, Taeko
    Emoto, Kahaku
    Yang, Lili
    Arora, Vipin
    Gaich, Carol L.
    Rooney, Terence
    Schlichting, Douglas E.
    Macias, William
    de Bono, Stephanie
    Weinblatt, Michael E.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [30] Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study
    Fleischmann, Roy
    Burmester, Gerd-Rudiger
    Combe, Bernard
    Curtis, Jeffrey R.
    Hal, Stephen
    Haraoui, Boulos
    van Vollenhoven, Ronald
    Cioffi, Christopher
    Ecoffet, Cecile
    Ionescu, Lucian
    Gervitz, Leon
    Peterson, Luke
    Smolen, Josef
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345